Company news
Tetra Bio-pharma Inc. (OTC:TBPMQ) news
Tetra Bio-pharma Inc. news releases on 6ix. Latest, Feb 10, 2023: Tetra Bio-Pharma Announces Listing to OTCPink Market
Press releases & updates
Tetra Bio-Pharma Announces Listing to OTCPink Market
February 10, 2023
REDUVO™ Marketing Approval on the Right Path
December 22, 2022
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
December 6, 2022
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
November 29, 2022
Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission
November 18, 2022
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean
October 27, 2022
Tetra and Prepaire Jointly Apply to BARDA for Funding
October 11, 2022
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean
September 8, 2022
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
September 6, 2022
Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean
August 10, 2022
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections
August 10, 2022
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
July 12, 2022
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
June 6, 2022
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
May 31, 2022
Tetra Bio-Pharma Appoints Chief Financial Officer
May 30, 2022
Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD
May 18, 2022
Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate
May 17, 2022
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
May 10, 2022
Tetra Bio-Pharma and Cannvalate Enter Into Partnership
May 5, 2022
Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA
March 17, 2022
Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD
March 8, 2022
Tetra Bio-Pharma Provides Management Update
February 28, 2022
Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement
February 22, 2022
Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec
February 16, 2022
Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma
February 14, 2022
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna
February 14, 2022
Tetra Bio-Pharma Announces Closing of $2.1 Million Marketed Public Offering of Units
December 21, 2021
REPEAT – Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units
December 15, 2021
Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of Units
December 14, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
December 7, 2021
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units
December 1, 2021
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
November 29, 2021
Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™
November 29, 2021
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
November 3, 2021
DGAP-News: Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF(TM) from the European Medicines Agency
October 20, 2021
Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency
October 21, 2021
DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM)
October 13, 2021
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
October 14, 2021
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
October 5, 2021
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
September 2, 2021
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
July 29, 2021
Tetra Bio-Pharma Engages Christine Caron as Patient Partner
July 22, 2021
Tetra Bio-Pharma Accelerates REBORN1© Trial
July 12, 2021
Tetra Bio-Pharma Announces Change in Management
June 25, 2021
Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003
June 21, 2021
Next Super Stocks on the Move: Tetra Bio-Pharma, Red Light Holland, FansUnite, and Skylight Health
June 11, 2021
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
June 1, 2021
Tetra Bio-Pharma Announces Voting Results of 2021 Annual General and Special Meeting
May 27, 2021
Tetra Bio-Pharma Announces Clinical Advancements and Establishment of At-the-Market Equity Program
May 28, 2021
Tetra Bio-Pharma Announces Exercise of Over-Allotment Option in Connection with Bought Deal Financing
May 21, 2021